New Pluvicto data point to a potential wider indication, but Novartis leaves regulatory timeline up in the air: #ESMO23

MADRID — No­var­tis’ ra­dio­phar­ma­ceu­ti­cal drug Plu­vic­to staved off prostate can­cer pro­gres­sion for a me­di­an of six months longer than hor­mone ther­a­py in a piv­otal study, open­ing up the pos­si­bil­i­ty of the drug as an ear­li­er treat­ment op­tion.

The Phase III study, known as PS­MAfore, in­clud­ed 468 prostate can­cer pa­tients who had pre­vi­ous­ly re­ceived one an­dro­gen re­cep­tor ther­a­py but not chemother­a­py. Those who re­ceived Plu­vic­to lived for a me­di­an of 12 months be­fore their dis­ease pro­gressed com­pared to a me­di­an of 5.6 months for those who re­ceived an­dro­gen re­cep­tor ther­a­py — ei­ther Zyti­ga or Xtan­di.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.